Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015;1(4):466-74.

Ryerson LZ, Kister I, Snuderl M, Magro C, Bielekova B. Incomplete Susac syndrome exacerbated after natalizumab. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e151.

Ginter PS, Scognamiglio T. Papillary thyroid carcinoma with nodular fasciitis-like stroma: a usual entity with distinctive morphology. Int J Surg Pathol. 2015;23(4):305-7.

Cho H, Herzka T, Stahlhut C, Watrud K, Robinson BD, Trotman LC. Rapid in vivo validation of candidate drivers derived from the PTEN-mutant prostate metastasis genome. Methods. 2015;77-78:197-204.

Huang T-, Renuse S, Pinto S, Kumar P, Yang Y, Chaerkady R, et al. Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst. 2015;11(1):197-207.

Jain M, Robinson BD, Salamoon B, Thouvenin O, Boccara C, Mukherjee S. Rapid evaluation of fresh ex vivo kidney tissue with full-field optical coherence tomography. J Pathol Inform. 2015;6:53.

Solomon JP, Hansel DE. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates. Adv Anat Pathol. 2015;22(2):102-12.

Cacciatore S, Loda M. Innovation in metabolomics to improve personalized healthcare. Ann N Y Acad Sci. 2015;1346(1):57-62.

Zhan Y, Kost-Alimova M, Shi X, Leo E, Bardenhagen JP, Shepard HE, et al. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. Epigenetics Chromatin. 2015;8:37.

Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, et al. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget. 2015;6(7):4863-87.